203 related articles for article (PubMed ID: 18636661)
1. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.
Moehler M; Frings C; Mueller A; Gockel I; Schimanski CC; Biesterfeld S; Galle PR; Holtmann MH
World J Gastroenterol; 2008 Jul; 14(26):4156-67. PubMed ID: 18636661
[TBL] [Abstract][Full Text] [Related]
2. Combination effect of cetuximab with radiation in colorectal cancer cells.
Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH
Tumori; 2010; 96(5):713-20. PubMed ID: 21302618
[TBL] [Abstract][Full Text] [Related]
3. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
Cappuzzo F; Finocchiaro G; Rossi E; Jänne PA; Carnaghi C; Calandri C; Bencardino K; Ligorio C; Ciardiello F; Pressiani T; Destro A; Roncalli M; Crino L; Franklin WA; Santoro A; Varella-Garcia M
Ann Oncol; 2008 Apr; 19(4):717-23. PubMed ID: 17974556
[TBL] [Abstract][Full Text] [Related]
4. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
5. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
6. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
7. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma.
Onogawa S; Kitadai Y; Tanaka S; Kuwai T; Kimura S; Chayama K
Cancer Sci; 2004 Jan; 95(1):32-9. PubMed ID: 14720324
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of cetuximab efficacy.
Vallböhmer D; Zhang W; Gordon M; Yang DY; Yun J; Press OA; Rhodes KE; Sherrod AE; Iqbal S; Danenberg KD; Groshen S; Lenz HJ
J Clin Oncol; 2005 May; 23(15):3536-44. PubMed ID: 15908664
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S; Wissmann C; Jöns T; Vieth M; Hertel J; Gretschel S; Schlag PM; Kemmner W; Höcker M
J Clin Oncol; 2006 Jan; 24(2):228-40. PubMed ID: 16344322
[TBL] [Abstract][Full Text] [Related]
10. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.
Goetz M; Hoetker MS; Diken M; Galle PR; Kiesslich R
Endoscopy; 2013 Jun; 45(6):469-77. PubMed ID: 23580409
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis.
Hu WG; Li JW; Feng B; Beveridge M; Yue F; Lu AG; Ma JJ; Wang ML; Guo Y; Jin XL; Zheng MH
Eur Surg Res; 2007; 39(4):229-38. PubMed ID: 17446709
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
Kim JY; Bae BN; Kwon JE; Kim HJ; Park K
APMIS; 2011 Jul; 119(7):449-59. PubMed ID: 21635552
[TBL] [Abstract][Full Text] [Related]
13. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
14. First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Xu W; Jing H; Zhang F
Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.
Chan E; Lafleur B; Rothenberg ML; Merchant N; Lockhart AC; Trivedi B; Chung CH; Coffey RJ; Berlin JD
Am J Clin Oncol; 2011 Dec; 34(6):581-6. PubMed ID: 21217396
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
20. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
